HR Execs on the Move

Cellarity

www.cellarity.com

 
Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.cellarity.com
  • 100 Technology Square 6th Floor
    Cambridge, MA USA 02140
  • Phone: 617.500.7775

Executives

Name Title Contact Details
Anna O`Driscoll
Chief People Officer Profile

Similar Companies

Active Motif

Active Motif is a fast-growing biotechnology company that is dedicated to developing new and innovative tools & techniques that help analyze nuclear function. Our employees are our biggest asset and our corporate policy is to treat them as such. This

Locana

Locana is a RNA-targeting gene therapy company

Roche NimbleGen

Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobioticâ„¢ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.

AviadoBio

At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company`s technology is based on pioneering research from King`s College London and the UK Dementia Research Institute.